About Rznomics
Rznomics is a company founded in 2017 by Seong-Wook Lee.. Rznomics has raised $39.8 million across 2 funding rounds from investors including SBI Mutual Fund, SBI Investment Korea and Korea Development Bank Europe. Rznomics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Revolution Medicines, among others.
- Founders Seong-Wook Lee
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rznomics Inc.
-
Annual Revenue
-
Net Profit
$-24.5 M (USD)-39as on Dec 31, 2022
-
EBITDA
$-24.5 M (USD)-39as on Dec 31, 2022
-
Total Equity Funding
$39.8 M (USD)
in 2 rounds
-
Latest Funding Round
$29.76 M (USD), Series C
Jun 08, 2022
-
Investors
SBI Mutual Fund
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rznomics
Rznomics is a publicly listed company on the KRX with ticker symbol 476830 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Rznomics
Rznomics has successfully raised a total of $39.8M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $29.76 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $29.8M
-
First Round
First Round
(20 Sep 2019)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series C - Rznomics | Valuation |
investors |
|
| Sep, 2019 | Amount | Series A - Rznomics | Valuation | SBI Investment Korea , Korea Development Bank Europe |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Rznomics
Rznomics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include SBI Mutual Fund, SBI Investment Korea and Korea Development Bank Europe. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment services are offered by AON Investment in Seoul.
|
Founded Year | Domain | Location | |
|
PE firm investing in South Korea and the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rznomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Rznomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rznomics Comparisons
Competitors of Rznomics
Rznomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics and Revolution Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rznomics
Frequently Asked Questions about Rznomics
When was Rznomics founded?
Rznomics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Who is the current CEO of Rznomics?
Seong-Wook Lee is the current CEO of Rznomics. They have also founded this company.
Is Rznomics a funded company?
Rznomics is a funded company, having raised a total of $39.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10.04M, raised on Sep 20, 2019.
What does Rznomics do?
Rznomics was founded in 2017 as a biotechnology firm specializing in RNA platform technology for drug development. Gene therapy products are created to address cancers, degenerative conditions, hereditary liver diseases, and related disorders. Operations focus on innovative treatments, with lead candidates including RZ001 for cancer, RZ002, and RZ003 targeted at Alzheimers disease. The company operates within the pharmaceutical sector, emphasizing RNA-based solutions for unmet medical needs.
Who are the top competitors of Rznomics?
Rznomics's top competitors include Moderna, Jazz Pharmaceuticals and Spark Therapeutics.
Is Rznomics publicly traded?
Yes, Rznomics is publicly traded on KRX under the ticker symbol 476830.
Who are Rznomics's investors?
Rznomics has 11 investors. Key investors include SBI Mutual Fund, SBI Investment Korea, Korea Development Bank Europe, AON Investment, and Partners Investment.
What is Rznomics's ticker symbol?
The ticker symbol of Rznomics is 476830 on KRX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.